Market Place
Sourcing Support
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
07 Aug 2024 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16 Jul 2024 //
GLOBENEWSWIRE
Aeterna Announces Last Patient Trial of Childhood Hormone Deficiency
13 Jun 2024 //
GLOBENEWSWIRE
Aeterna Zentaris and Ceapro Complete Merger Transaction
03 Jun 2024 //
GLOBENEWSWIRE
Aeterna Zentaris Updates On AGM Timing, Due Bill Redemption
29 May 2024 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
17 May 2024 //
GLOBENEWSWIRE
Aeterna Zentaris Reports First Quarter 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Effective Date of Share Consolidation
01 May 2024 //
GLOBENEWSWIRE
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
28 Mar 2024 //
GLOBENEWSWIRE
Aeterna Zentaris Reports Q4 and FY23 Results & Completion of DETECT-Trial
27 Mar 2024 //
GLOBENEWSWIRE
Aeterna Zentaris & Ceapro Merger Approved by Securityholders at Special Meetings
12 Mar 2024 //
GLOBENEWSWIRE
Ceapro Inc. Announces the Mailing of Meeting Materials
15 Feb 2024 //
GLOBENEWSWIRE
Aeterna Zentaris and Ceapro Announce Merger of Equals
14 Dec 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
11 Oct 2023 //
GLOBENEWSWIRE
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Outlines Progress on Development Pipeline Programs
13 Jul 2023 //
GLOBENEWSWIRE
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
05 Jul 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
14 Jun 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
15 May 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Reports First Quarter 2023 Financial Results
09 May 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Provides Update on Macrilen (Macimorelin)
05 Apr 2023 //
GLOBENEWSWIRE
Aeterna Zentaris 4Q & 2022 FYR
23 Mar 2023 //
GLOBENEWSWIRE
Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris
16 Mar 2023 //
BUSINESSWIRE
Pharmanovia to Market GHRYVELIN in the EEA and UK as Diagnostic Test for GHD
16 Mar 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
17 Jan 2023 //
GLOBENEWSWIRE
Aeterna discontinues vaccine development; Idera rebrands as Aceragen
17 Jan 2023 //
ENDPTS
Aeterna Zentaris to Present at Virtual Investor 2023 Companies to Watch Event
10 Jan 2023 //
GLOBENEWSWIRE
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin)
29 Aug 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Reports Q2 2022 Financial Results and Recent Highlights
03 Aug 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Effective Date of Share Consolidation
18 Jul 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
15 Jul 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
06 Jul 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
21 Jun 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Achieves Proof-of-Concept for NMOSD with AIM Biological Program
13 Jun 2022 //
GLOBENEWSWIRE
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
09 Jun 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders
16 May 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™
25 Apr 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin
19 Apr 2022 //
GLOBENEWSWIRE
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
12 Apr 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Abstract Accepted at 13th International Congress
11 Apr 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Aeterna Zentaris pivotal growth hormone deficiency trial sees recruitment delays
22 Mar 2022 //
SEEKING ALPHA
Aeterna Zentaris Expands Program with Julius-Maximilians-University
10 Mar 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150
02 Mar 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Granted 180-Day Extension for Compliance with Min. Bid Price
26 Jan 2022 //
GLOBENEWSWIRE
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
23 Dec 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
23 Dec 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Announces Final Settlement of Previously Disclosed
03 Jun 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin
17 May 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial
13 May 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Announces the Selection of a Development in the DC-PTH Program
06 May 2021 //
YAHOO
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering
19 Feb 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Increases Previously Announced Bought Deal Offering
16 Feb 2021 //
GLOBENEWSWIRE
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
16 Feb 2021 //
GLOBENEWSWIRE
Aeterna Zentaris signs agreement to evaluate oral Covid-19 vaccine
03 Feb 2021 //
PHARMACEUTICAL-TECHNOLOGY
